IC-OS Weekly Webinar - Heart Failure with Preserved Ejection Fraction in Cardio-Oncology: Is There a One Stop Best Imaging Test?

Dr Arjun K Ghosh MBBS, MSc, PhD, FHEA, FACC, FESC, FRCP, FICOS is a Consultant Cardiologist at Barts Heart Centre (BHC), St. Bartholomew’s Hospital, London and at University College London Hospital (UCLH). He is the first cardiologist in the UK to be appointed specifically in cardio-oncology and helped establish Cardio-Oncology services at both these hospitals which are now amongst the biggest services worldwide. Arjun leads the cardio-oncology service at UCLH. Arjun is also actively involved in developing cardio-oncology curricula and guidelines and changing practice through the British Society of Echocardiography, British Cardio-Oncology Society and International Cardio-Oncology Society and UK Specialist Advisory Committee (SAC). He was joint first author of the first British cardio-oncology guidelines published earlier this year. He runs the UK’s only national Cardio-Oncology Study Day and help organise the only pan-European Cardio-oncology Symposium. Outside of the interesting world of cardiology’s newest subspecialty Arjun is involved in cardiac MRI (CMR) and cardio-oncology echocardiography and has several national and international leadership and management positions at the British Cardiovascular Society, the Royal Society of Medicine, the British Cardio-Oncology Society and the International Cardio-Oncology Society. He is the co-host of the ICOS podcast and has recently been appointed to the ACC Cardio-Oncology Leadership Council. You can find him on Twitter @arjunkg.

Dr. Bénédicte Lefebvre is an Assistant Professor of Clinical Medicine at the University of Pennsylvania. Dr. Lefebvre earned her medical degree from McGill University, Montreal, Canada where she also completed her training in internal medicine and general adult cardiology. She then completed a two-year fellowship in advanced cardiac imaging at the University of Pennsylvania specializing in echocardiography, structural echocardiography and cardiac magnetic resonance. Afterwards, she underwent a cardio-oncology fellowship at the University of Pennsylvania. Dr. Lefebvre’s research focuses on the cardiovascular effects of CAR T cells and the use of cardiac imaging and biomarkers to detect cardiotoxicity.

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.